Economic benefit of prescribing an adjusted renal dose of <scp>dipeptidyl peptidase</scp> IV inhibitors in type 2 diabetes patients with chronic kidney disease
摘要
Highlights Based on nationwide insurance data in Korea, the use of dipeptidyl peptidase IV inhibitors (DPP-IVi) not requiring renal dose adjustment (NRDA DPP-IVi) is widespread in the type 2 diabetes chronic kidney disease (T2D CKD) population. Instead of prescribing NRDA DPP-IVi, the use of DPP-IVi requiring renal dose adjustment with appropriate renal dose adjustments in T2D CKD patients can achieve a considerable annual cost saving of up to 7.8%.
引用本文（GB/T 7714）
Sun Joon Moon, Young Min Cho. Economic benefit of prescribing an adjusted renal dose of <scp>dipeptidyl peptidase</scp> IV inhibitors in type 2 diabetes patients with chronic kidney disease[J]. Journal of Diabetes, 2020.
引文网络
本站仅收录题录与摘要供学习参考，全文版权归属出版方；如有侵权请联系我们删除。